Pakistan News Service

Thursday May 24, 2018, Ramadan 9, 1439 Hijri
Logo Logo
Pakistan News Home -> Health -> News Details

Prostate Cancer Vaccine may Improve Survival

19 February, 2013

ISLAMABAD: A prostate cancer vaccine extends the lives of patients, even after all other treatments have failed.

In what doctors are calling a potentially "landmark" study, the vaccine, called Provenge, tripled the survival of men with advanced prostate cancer.

Provenge is not a vaccine in the way that most people think of vaccines. Unlike most vaccines, which prevent diseases, this vaccine is used to treat men who already have prostate cancer.

Researcher Eric J. Small, MD, says this is the first nonchemotherapy drug treatment to improve survival. He presented the findings today at the first 2005 Multidisciplinary Prostate Cancer Symposium in Orlando, Fla.

Small, professor of medicine and urology at the University of California, San Francisco School of Medicine, says the treatment was far less toxic and better tolerated than chemotherapy. Provenge's only side effects were flu-like symptoms lasting just 24 hours.

Phillip Kantoff, MD, a medical oncologist at the Dana Farber Cancer Institute in Boston, calls the study a "potentially huge finding" and says it "represents the first vaccine approach in prostate cancer that shows a survival advantage."

The research involved 127 men, aged 47 to 85, with metastatic prostate cancer. None of the men had symptoms from the cancer, such as pain. The men no longer were responding to traditional hormone treatment for prostate cancer.

The men were divided into two groups -- 82 men received the Provenge prostate cancer vaccine, while 45 men were given a placebo vaccine. Three injections were given, two weeks apart.

Overall, Provenge prolonged life by as much as 4.5 months over those patients given the placebo vaccine.

Perhaps more significant were the results seen three years after the vaccine was given. At that point, 34% of vaccine patients were still alive compared with 11% of men that received the placebo vaccine.

Experts say it's important news for the more than 232,000 men diagnosed with prostate cancer each year in the U.S. It is the most common cancer among American men, killing some 30,000 each year.

The vaccine is still experimental and not yet available outside of clinical trials. Dendreon - the vaccine's maker - says the vaccine is being "fast-tracked" through the FDA. But it is still not likely to be up for approval until 2006 at the earliest. Results from additional trials are not expected until late 2005.


 What do you think about the story ? Leave your comments!

Heading (Optional)
Your Comments: *

Your Name:*
E-mail (Optional):
City (Optional):
Country (Optional):
Field marked(*) are mandatory.
Note. The PakTribune will publish as many comments as possible but cannot guarantee publication of all. PakTribune keeps its rights reserved to edit the comments for reasons of clarity, brevity and morality. The external links like http:// https:// etc... are not allowed for the time being to be posted inside comments to discourage spammers.

  Speak Out View All
Military Courts
Imran - Qadri long march
Candid Corner
Exclusive by
Lt. Col. Riaz Jafri (Retd)
Pakistan itself a victim of state-sponsored terrorism: Qamar Bajwa
Should You Try Napping During the Workday?
Suggested Sites